Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Treatment using statin has been decreased the risk of cardiovascular events in pre-dialysis
CKD population. Supplementation with omega-3 fatty acid (FA) lowers the risk of
cardiovascular death in patients with myocardial infarction. This cardioprotective effect of
omega-3 FA can be explained by anti-inflammatory, anti-oxidative, or anti-thrombotic effects.
Statin such as pravastatin is also known to have anti-inflammatory and antioxidant
properties, suggesting that statin may replace the cardioprotective effect of omega-3 fatty
acids. Erythrocyte membrane oleic acid is significantly higher in patients with acute
coronary syndrome than control subjects. The cardioprotective effect of omega-3 FA may also
be related to decreased oleic acid content of erythrocyte membrane. There is no report about
the effect of statin on FA including erythrocyte membrane oleic acid. As omega-3 FAs are
recognized as therapeutic agents for reducing triglycerides, statin may affect on the
erythrocyte membrane FA. Therefore, pravastatin supplementation can modify erythrocyte
membrane FA contents including oleic acid in CKD patients.